Which model is best for testing symptomatic relief?

The 6-OHDA rat model is preferred for symptomatic relief and L-DOPA-induced dyskinesia (LID) studies due to its robust motor asymmetry.

Can you confirm Blood-Brain Barrier (BBB) penetration?

Yes, we utilize LC-MS/MS to quantify drug concentrations in both plasma and brain tissue/ Cerebrospinal Fluid (CSF) to determine the Brain-to-Plasma Ratio or Unbound Brain-to-Unbound Plasma Ratio values.

How do you ensure the stability of the AAV expression?

We use validated viral titers and perform longitudinal IHC to verify consistent overexpression of the target protein across the study duration.

How do you verify dopaminergic neuron loss?

We use Tyrosine Hydroxylase (TH) immunohistochemistry and stereological counting in the substantia nigra pars compacta (SNpc)c and striatum.

Can you evaluate non-motor symptoms of PD?

Yes, we offer behavioral assays for cognitive impairment, anxiety-like behavior, and gastrointestinal motility.

Parkinson's Disease (PD) Modeling & Pharmacodynamics Services

Introduction

Parkinson's disease is the second most common neurodegenerative disease and remains a profound challenge in neurodegenerative research, characterized by the progressive loss of dopaminergic neurons and the accumulation of α-synuclein. Addressing this complexity requires a sophisticated balance between replicating motor symptoms and capturing the underlying molecular pathology. Creative Biolabs' platform provides a robust bridge from early discovery to clinical entry by offering a full suite of preclinical services designed to close this gap. By integrating industry-standard neurotoxic models with advanced genetic and proteinopathy-based modeling and sophisticated pharmacodynamic (PD) readouts, we provide the high-fidelity data necessary to validate targets, clarify mechanisms of action, and de-risk the path to clinical validation for your therapeutic candidates.

Fig.1 The introduction of Parkinson's disease. (OA Literature) Fig. 1 Multifactorial pathophysiology, biomarkers, and diagnostic precision of Parkinson's disease.¹

Available Parkinson's Disease Models

Creative Biolabs provides a specialized suite of Parkinson's Disease models (e.g., rodents, dogs, NHPs) designed to validate diverse therapeutic modalities, from symptomatic relief to disease-modifying gene therapies. By integrating these robust models across species, including mice, rats, and NHPs, we provide the precise pathological context needed to accelerate your PD drug development.

AD Models	Modeling & Application Values	Animal Species
MPTP-Induced PD Model	Systemic injection of MPTP neurotoxin to mimic acute dopaminergic cell loss. Gold standard for mitochondrial and anti-apoptotic drug testing. Ideal for rapid neuroprotection screening: Evaluates MAO-B inhibitors (e.g., Selegiline, Rasagiline) and GLP-1 agonists (e.g., Exenatide).	Mouse, Dog, NHPs
6-OHDA Unilateral Lesion PD Model	Stereotaxic microinjection of 6-OHDA to create a unilateral lesion, using the unaffected side as an internal control. Highly sensitive for evaluating symptomatic relief and motor recovery. Excellent for assessing motor recovery & LID assessment: Evaluates L-DOPA efficacy, dopamine agonists (e.g., Pramipexole), and dyskinesia treatments (e.g., Amantadine).	Rat
AAV-Mediated Alpha-Synuclein Overexpression PD Model	Stereotaxic delivery of Adeno-Associated Virus (AAV) carrying human wild-type or mutant (e.g., A53T) α-synuclein genes. Mimics the progressive proteinopathy and Lewy body-like pathology of PD. Preferred model for testing gene therapies, Aβ orα-synuclein clearance agents, and drugs targeting chronic neurodegeneration. Evaluates α-synuclein antibodies (e.g., Prasinezumab), aggregation inhibitors (e.g., Anle138b), and gene therapies (e.g., BIIB094).	Mouse

Evaluation Platform

We provide a multi-dimensional assessment framework to capture the full spectrum of Parkinson's Disease progression:

Behavioral Phenotyping
- Motor Function & Coordination: Characterized through automated gait analysis, the Rotarod, Pole Test, and Cylinder Test to quantify bradykinesia, tremors, and postural asymmetry.
- Non-Motor Symptoms (NMS):
  - Olfactory Dysfunction: Assessed via Buried Pellet and Novel Scent tests to detect early-stage hyposmia.
  - Autonomic & GI Health: Evaluation of stool frequency, gastric emptying, and colonic motility to monitor enteric nervous system involvement.
  - Circadian & Sleep Monitoring: Utilizing polysomnography and EEG to profile sleep latency and disruptions in sleep architecture.
- Neuropsychiatric & Cognitive Profiling:
  - Affective States: Measuring anxiety and depression-like behaviors via Elevated Plus Maze, Forced Swim Test, and Sucrose Preference assays.
  - Cognitive Integrity: Utilizing Morris Water Maze, Novel Object Recognition, and Fear Conditioning to assess executive dysfunction and memory deficits.
Neurochemical & Molecular Analysis
- Dopaminergic Integrity: Quantitative analysis of striatal dopamine (DA) and its metabolites (DOPAC, HVA) using High-Performance Liquid Chromatography (HPLC).
- Biomarker Profiling: High-sensitivity ELISA (MSD) for neuroinflammatory cytokine profiling and Western Blotting for quantifying synaptic markers (e.g., Synaptophysin).
Quantitative Histopathology
- Structural Validation: Unbiased stereological counting of TH⁺ neurons in the Substantia Nigra (SNpc) to verify neuroprotection.
- Proteinopathy Quantification: High-resolution IHC/IF to visualize and quantify p-S129 α-synuclein aggregate burden and spreading.

Applications

Mechanism of Action (MoA) Elucidation: Confirming target engagement, such as LRRK2 inhibition or α-synuclein clearance.
Target Validation: Confirming the biological relevance of novel PD targets in vivo.
Lead Optimization: Comparing multiple candidates to identify those with superior brain penetration and efficacy.
Biomarker Discovery: Identifying and validating translational markers (e.g., Cerebrospinal Fluid α-synuclein, Neurofilament Light Chain).
Safety & Dosing: Establishing PK/PD relationships to guide First-in-Human (FIH) dose projections.

Our Advantages

Expert Insight: Studies are designed and executed by a team of neuroscientists with decades of experience in basal ganglia circuitry.
High Translational Fidelity: Our models replicate key Parkinson's disease hallmarks, including striatal dopamine depletion and progressive motor deficits.
Precision Targeting: Our stereotaxic injections are guided by high-resolution brain atlases to ensure consistent lesion placement.
Precision PD Endpoints: We utilize high-sensitivity assays (e.g., MSD, LC-MS/MS) and automated behavioral tracking.
Translational Readouts: We combine these models with HPLC for neurotransmitter analysis and Tyrosine Hydroxylase (TH) staining for histological validation.
Longitudinal Monitoring: For AAV models, we offer long-term tracking to observe the slow, progressive nature of the disease, which better reflects human clinical progression.
Integrated Solutions and PK/PD: We provide a seamless workflow from surgical modeling and drug administration to complex pathological analysis. Simultaneous monitoring of drug exposure and biological response to reduce development risk.
Flexible Customization: Tailored study designs to accommodate specific drug mechanisms, from small molecules to ASO therapies.

Work with Us

Inquiry Stage:

Summarize the project requirements and fill in the information collection form.
Sign a CDA from both parties to further communicate information, such as targets.
Select an animal model, discuss experimental design, and determine assay parameters.
Project costing and project schedule forecasting.

Project Start:

We provide a detailed project plan, including the required sample quantities, methods, and protocols.
Both parties confirm the project details and start the project.
Confirm the timeline of the project.

Project Progress:

We provide periodic results and information on the animal's condition.
We will work together to make project adjustments as necessary.

Project Completion:

We provide a comprehensive project report promptly.
We arrange transportation for the produced samples.
We provide a discussion of the project results and help to arrange the next steps.

After-Sales Support:

Data storage and archiving.

Get in touch!

FAQs

Q: Which model is best for testing symptomatic relief?

A: The 6-OHDA rat model is preferred for symptomatic relief and L-DOPA-induced dyskinesia (LID) studies due to its robust motor asymmetry.
Q: Can you confirm Blood-Brain Barrier (BBB) penetration?

A: Yes, we utilize LC-MS/MS to quantify drug concentrations in both plasma and brain tissue/ Cerebrospinal Fluid (CSF) to determine the Brain-to-Plasma Ratio or Unbound Brain-to-Unbound Plasma Ratio values.
Q: How do you ensure the stability of the AAV expression?

A: We use validated viral titers and perform longitudinal IHC to verify consistent overexpression of the target protein across the study duration.
Q: How do you verify dopaminergic neuron loss?

A: We use Tyrosine Hydroxylase (TH) immunohistochemistry and stereological counting in the substantia nigra pars compacta (SNpc)c and striatum.
Q: Can you evaluate non-motor symptoms of PD?

A: Yes, we offer behavioral assays for cognitive impairment, anxiety-like behavior, and gastrointestinal motility.

Published Data

In an MPTP-induced mouse model of Parkinson's Disease, Trolox significantly upregulates the expression of key dopaminergic proteins, including TH, Dopamine Transporter (DAT), and Vesicular Monoamine Transporter 2 (VMAT2), within the striatum and the SNpc. Furthermore, Trolox treatment increases the count of TH-positive neurons, thereby preserving the structural and functional integrity of the dopaminergic system.

Fig.2 The therapeutic effect of Trolox in the MPTP-induced mouse model of Parkinson's Disease. (OA Literature) Fig. 2 Effects of Trolox on the expression of dopamine-related proteins in the MPTP-induced Parkinson's Disease mouse models.²

References

Tanaka, Masaru. "Parkinson's Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation." Cells vol. 14,15 1161. Distributed under Open Access license CC BY 4.0, with modification. https://doi.org/10.3390/cells14151161
Atiq, Abubakar et al. "Vitamin E Analog Trolox Attenuates MPTP-Induced Parkinson's Disease in Mice, Mitigating Oxidative Stress, Neuroinflammation, and Motor Impairment." International Journal of Molecular Sciences vol. 24,12 9942. Distributed under Open Access license CC BY 4.0, with modification. https://doi.org/10.3390/ijms24129942